Navigation Links
Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
Date:9/15/2008

Findings Presented At The American Society Of Clinical Psychopharmacology

Meeting

WELLESLEY HILLS, Mass., Sept. 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee of the assets of Spherics, Inc. ("Spherics") for the benefit of creditors, announced today that all oral drug delivery intellectual property will be sold at a sealed bid auction on October 10, 2008.

Topamax(R) produces adverse effects on cognitive functions at rates of over 40% in subjects with epilepsy. These effects manifest as confusion, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language and word-finding difficulties. Using computerized Neuropsychological Test Battery (CNTB) modules, measuring attention/concentration, verbal and visual memory, and working memory, as well as two paper and pencil processing speed tests: Symbol Digit Modalities Test (SDMT) and verbal associative fluency test (FAS), the novel extended release Topiramate formulation (SRx-502) was shown to be associated with both significantly reduced cognitive impairment and fewer reduced adverse events.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's office -- jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package and access to the Spherics electronic data room.

About Spherics

Spherics has built a strong intellectual property position around its drug delivery technologies and products. The Company has a broad range of issued US and international patents that they have applied to their four central nervous system products. These patents cover polyanhydride-based bioadhesive polymers and nanotechnology (PIN(TM)). In addition to these issued patents, Spherics has filed numerous applications covering compositions of matters of its proprietary polymers (SPHEROMERS(TM)), novel oral delivery systems (including BIOGIT(TM), BIOROD(TM) and PIN(TM)), manufacturing methods, methods of use, formulations and product compositions.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-four (34) years. His most recent Assignment for the Benefit of Creditors in the Biotech field was ActivBiotics, Inc.


'/>"/>
SOURCE Spherics, Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
2. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
3. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
4. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
5. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
6. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
7. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
8. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
9. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
10. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
11. CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... Top deals by value - Deals listed by company ... The report provides understanding and access to the partnering ... healthcare companies. The report provides an analysis of ...
(Date:1/19/2017)... , Jan. 19, 2017 Many patients ... for their medication when a pharmacy just a few ... prescription.  To alleviate this problem Medicationdiscountcard.com has ... to see exactly how much their medication will cost ... Made Easy Medicationdiscountcard.com ...
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... blood analysis instruments and consumables for the medical and ... discuss its financial results for the third quarter fiscal ... be at 4:15 p.m. ET on Thursday, January 26, ... third quarter fiscal year 2017 after the market closes ...
Breaking Medicine Technology:
(Date:1/19/2017)... Mississippi (PRWEB) , ... January 19, 2017 , ... St. ... Siena Center. , Siena Center is a skilled nursing facility on the grounds of ... and semiprivate rooms. It recently was voted the best nursing home in Mississippi for ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... in the 2017 Spring Create Real Impact contest from Impact Teen Drivers and ... at http://www.createrealimpact.com . , Educational grants totaling $15,000 will be awarded ...
(Date:1/19/2017)... CA (PRWEB) , ... January 18, 2017 , ... The ... while driving during a rain storm by slowing down and increasing the space between ... Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain ...
(Date:1/19/2017)... Norwalk, CT (PRWEB) , ... January 19, 2017 , ... ... Dr. Sang H. Kim, a highly experienced and compassionate dermatologist. Dr. Kim brings ... skincare center . , “It is with considerable pleasure to welcome back Dr. Kim ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sales Focus Inc. ... clients into the US market. , Over the past 20 years SFI has been ... weeks SFI has launched six new clients into the US market. The new ...
Breaking Medicine News(10 mins):